Furthermore, based on this rationale, various PARP inhibitors are FDA-approved drugs with cancer patients with defects in BRCA1/2 such as ovary, breast, and prostatic cancer (OncoKB database, https://www.oncokb.org, accessed July 31, 2020). Here, BRCA1 is linked to Familial prostate cancer.